RxDoctor Payments Data

Olusegun Ogunlesi

Infectious Disease · Mentor, OHNPI 1013182013

Payments from drug & device makers

$3,496in general payments, 2019–2025

Across 137 payments — averaging $25.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$619
  • Smith+Nephew$572
  • AbbVie$350
  • Gilead$272
  • Organogenesis Inc.$221
  • Viiv Healthcare Company$219
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,46999%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,496 in reported general payments places this provider in the 75th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$309,685
Medicare patients
854
Services billed
3,752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala41$174,909
TivicayDolutegravir Sodium35$95,783
Daptomycin77$85,049
DescovyEmtricitabine/Tenofov Alafenam14$46,949
IsentressRaltegravir Potassium22$46,244
TriumeqAbacavir/Dolutegravir/Lamivudi12$44,071
ErtapenemErtapenem Sodium83$34,307
Cefepime Hcl138$32,339
ZerbaxaCeftolozane/Tazobactam13$25,411
Vancomycin Hcl183$23,594
Meropenem87$16,734
CimduoLamivudine/Tenofovir Disop Fum11$14,798
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam68$14,271
CeftriaxoneCeftriaxone Sodium65$9,703
Etravirine11$7,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$272$221,85855 claims
Viiv Healthcare CompanyTivicay, Triumeq$219$139,85447 claims
MerckIsentress, Zerbaxa$619$71,65535 claims
Smith+NephewSantyl$572$3,22711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Mentor

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →